1-3 of 3
Nabeel Bardeesy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

Yi Sun, Luke Maggs, Apekshya Panda, Samuel J. Wright, Angelina M. Cicerchia, Anne Jenney, Matthew D. Perricone, Caitlin E. Mills, Giulia Cattaneo, Marco Ventin, Feng Chen, Martin Q. Rasmussen, Alex Miranda, Or-Yam Revach, Jacy Fang, Amina Fu, Peter J. Bowling, Tatyana Sharova, Aleigha Lawless, Peter K. Sorger, Nabeel Bardeesy, Xinhui Wang, Keith T. Flaherty, Genevieve M. Boland, Arnav Mehta, Moshe Sade-Feldman, Cristina R. Ferrone, Russell W. Jenkins
Journal: Cancer Immunology Research
Cancer Immunol Res OF1–OF19.
https://doi.org/10.1158/2326-6066.CIR-23-1011
Published: 09 January 2025
View article titled, TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Open the PDF for TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids in another window
Includes: Supplementary data
Journal Articles

Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen, Zohreh Amoozgar, Xin Liu, Shuichi Aoki, Zelong Liu, Sarah M. Shin, Aya Matsui, Alexei Hernandez, Zhangya Pu, Stefan Halvorsen, Pin-Ji Lei, Meenal Datta, Lingling Zhu, Zhiping Ruan, Lei Shi, Daniel Staiculescu, Koetsu Inoue, Lance L. Munn, Dai Fukumura, Peigen Huang, Slim Sassi, Nabeel Bardeesy, Won Jin Ho, Rakesh K. Jain, Dan G. Duda
Journal: Cancer Immunology Research
Cancer Immunol Res (2024) 12 (4): 400–412.
https://doi.org/10.1158/2326-6066.CIR-23-0486
Published: 02 April 2024
View article titled, Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Open the PDF for Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract B89: Dual PD-1 and VEGFR-2 blockade induces vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma

Meenal Datta, Kohei Shigeta, Tai Hato, Shuji Kitihara, Ivy X. Chen, Aya Matsui, Hiroto Kikuchi, Emilie Mamessier, Shuichi Aoki, Rakesh R. Ramjiawan, Hiroki Ochiai, Nabeel Bardeesy, Peigen Huang, Rakesh K. Jain, Mark Cobbold, Andrew X. Zhu, Dan G. Duda
Journal: Cancer Immunology Research
Cancer Immunol Res (2020) 8 (3_Supplement): B89.
https://doi.org/10.1158/2326-6074.TUMIMM19-B89
Published: 02 March 2020
View article titled, Abstract B89: Dual PD-1 and VEGFR-2 blockade induces vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma